Motilal Oswal: Laurus Labs’ Richcore Acquisition A Step Towards Strategic Diversification
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Laurus Labs Ltd. has acquired 73% stake in Richcore Lifesciences for a cash consideration of Rs 2.5 billion.
The acquisition is a step towards building a vertically integrated biotech segment and adds a new lever to growth.
It particularly provides capabilities in high growth areas of Recombinant (Rh) Proteins, Enzymes and Biological contract development and manufacturing organisation.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.